![](https://nthumb.tpgimages.com/mid2_ocom_img/c2NpZW5jZV9waG90bw==/1/2008041614/top_20080416145517_693.jpg/TOP03197888.jpg)
TGN1412 drug molecule. Computer model showing the secondary structure of the drug TGN1412. This drug was shown to have serious side effects during a clinical trial in the UK in 2006 when it caused systemic failure in 6 volunteers. The drug is a monoclonal antibody that activates T cells by binding to CD28 receptors on the cell's surface. T cells are a type of white blood cell and a component of the body's immune system.
px | px | dpi | = | cm | x | cm | = | MB |
Details
Creative#:
TOP03197888
Source:
達志影像
Authorization Type:
RM
Release Information:
須由TPG 完整授權
Model Release:
N/A
Property Release:
N/A
Right to Privacy:
No
Same folder images:
TGN1412MONOCLONALANTIBODYDRUGMOLECULEBIOCHEMISTRYPHARMACOLOGYMEDICINECHEMISTRYCOMPUTERMODELMOLECULARMODELCOMPUTERARTWORKONESINGLEMOLECULARCHEMICALMEDICALPHARMACOLOGICALILLUSTRATIONCHEMISTRYCHEMICALBIOCHEMISTRYBIOCHEMICALCOMPOUNDCOMPOUNDSMOLECULEMOLECULESPROTEINPROTEINSIMMUNOMODULATORYCLINICALTRIALSECONDARYSTRUCTUREBETASHEETSHEETSAGONISTCD28DRUGTRIALFAILURESIDEEFFECTEFFECTSCONTROVERSIALCD28-SUPERMAB
AGONISTANTIBODYARTWORKBETABIOCHEMICALBIOCHEMISTRYBIOCHEMISTRYCD28CD28-SUPERMABCHEMICALCHEMICALCHEMISTRYCHEMISTRYCLINICALCOMPOUNDCOMPOUNDSCOMPUTERCOMPUTERCONTROVERSIALDRUGDRUGEFFECTEFFECTSFAILUREILLUSTRATIONIMMUNOMODULATORYMEDICALMEDICINEMODELMODELMOLECULARMOLECULARMOLECULEMOLECULEMOLECULESMONOCLONALONEPHARMACOLOGICALPHARMACOLOGYPROTEINPROTEINSSECONDARYSHEETSHEETSSIDESINGLESTRUCTURETGN1412TRIALTRIAL